Smith & Nephew plc vs Materials Select Sector SPDR Fund — how do they compare? Smith & Nephew plc trades at $27.96 (market cap $11.62B), while Materials Select Sector SPDR Fund trades at $51.29. The key difference: Smith & Nephew plc pays a 2.86% dividend while Materials Select Sector SPDR Fund pays none, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | XLB | |
|---|---|---|
Market Cap | $11.62B | — |
Sector | Health | — |
52-Week High | $38.53 | $53.67 |
52-Week Low | $27.80 | $42.23 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.86% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The materials sector ETF benefits from AI infrastructure trends and strong Q2 earnings momentum across the sector. Recent news highlights potential opportunities in materials as investors rotate toward tangible assets.
The outlook for XLB appears constructive given sector tailwinds from infrastructure spending and AI buildout, though cyclical recovery may be partially priced in. Key risks include materials price volatility and geopolitical supply chain pressures. Analyst sentiment is mixed with some viewing current levels as fully valued after recent sector rebound.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →